Skip to content

Skin sensitivity test to evaluate sensitization of test product by standard HRIPT method

Repeated patch test (HRIPT) to examine the potential for cutaneous irritancy and allergic sensitization of SBL Baby Care Soap marketed by SBL Private Ltd, A-3 site IV, Sahibabad, Ghaziabad- 201010(UP) under complete occlusion on healthy male and female human subjects.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/03/040710
Enrollment
24
Registered
2022-03-02
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: SBL Baby Care Soap: Take 0.04 ml or 0.04 g of the sample using a micropipette or weighing balance (as applicable) on the patch and apply the patch on the upper arm or back. The patches

Sponsors

SBL Private ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects in the age group 18 - 55 years (both the ages inclusive). 2. Healthy male and female subjects. 3. Subjects with Fitzpatrick skin type III to V 4. Subjects willing to give written informed consent. 5. Subjects willing to maintain the patch test in position for 24 hours. 6. Subject having not participated in a similar investigation in the past one month. 7. Subjects willing to come for regular follow-up visits. 8. Subjects ready to follow instructions during the study period.

Exclusion criteria

Exclusion criteria: 1. Infection, allergy on the tested area. 2. Skin allergy, antecedents or atopic subjects. 3. Athletes and subjects with history of excessive sweating. 4. Cutaneous disease which may influence the study result. 5. Subject has used topical corticosteroids, topical immunomodulatory agents, or topical antibiotics on the extremity being evaluated within 7 days of skin barrier assessment 6. Subjects participating in any other cosmetic or therapeutic study. 7. Any history of underlying uncontrolled medical illness including diabetes, liver disease or history of alcoholism, HIV or any other serious medical illness.

Design outcomes

Primary

MeasureTime frame
1. Mean Cumulative irritancy Index using Draize scale for scoring the treatment sites (Erythema and Oedema) during Induction phase 2. Skin sensitisation using ICDRG scale for scoring the treatment sites as per IS 4011:2018 during challenge phaseTimepoint: o to 37 Days

Secondary

MeasureTime frame
To assess the adverse EventsTimepoint: 0 to 37 days

Countries

India

Contacts

Public ContactMs Shilpi Sachdeva

Basavanagudi Clinic

dermagiri@gmail.com9945054449

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026